Figure 2From: Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis The effect of adjusting for censoring in 3-year (left) and 5-year total costs (right). Matched pre-era CHOP and post-era RCHOP patients; all ages; all values discounted.Back to article page